Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Short term Debt (2021 - 2025)

Verrica Pharmaceuticals has reported Short term Debt over the past 4 years, most recently at $12.5 million for Q3 2025.

  • Quarterly results put Short term Debt at $12.5 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $12.5 million (changed N/A YoY), and the annual figure for FY2024 was $12.9 million, changed.
  • Short term Debt for Q3 2025 was $12.5 million at Verrica Pharmaceuticals, down from $12.7 million in the prior quarter.
  • Over the last five years, Short term Debt for VRCA hit a ceiling of $42.3 million in Q2 2022 and a floor of $12.5 million in Q3 2025.
  • Median Short term Debt over the past 4 years was $40.8 million (2021), compared with a mean of $30.0 million.
  • Peak annual rise in Short term Debt hit 3.27% in 2022, while the deepest fall reached 3.14% in 2022.
  • Verrica Pharmaceuticals' Short term Debt stood at $41.7 million in 2021, then rose by 1.44% to $42.3 million in 2022, then crashed by 69.41% to $12.9 million in 2024, then decreased by 3.71% to $12.5 million in 2025.
  • The last three reported values for Short term Debt were $12.5 million (Q3 2025), $12.7 million (Q2 2025), and $12.8 million (Q1 2025) per Business Quant data.